Ankylosing spondylitis - golimumab (TA233)
Fast, easy summary view of NICE guidance on 'lower limb peripheral arterial disease'
NICE recommends golimumab as a possible treatment for some adults with severe, active ankylosing spondylitis in the same circumstances as other drugs for the condition.
Who can have golimumab?
You should be able to have golimumab if:
- you have active spinal disease as assessed on two separate occasions 12 weeks apart, and
- you have tried at least two non-steroidal anti-inflammatory drugs (NSAIDs) but they have not worked.
When assessing your spinal disease, healthcare professionals should take into account any disabilities or difficulties in communicating you may have.
Your treatment should be started and supervised by a specialist who is experienced in diagnosing and treating ankylosing spondylitis. You should also have regular check-ups. Your treatment should continue only if your ankylosing spondylitis shows an adequate improvement. If the improvement is not maintained or if the drug stops working then treatment should be stopped.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: lower limb peripheral arterial disease
This page was last updated: 25 September 2012
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA233 Golimumab ar gyfer spondylitis ymasiol: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.